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A B S T R A C T
In this study, alterations in lipid metabolism associated with acute aﬂatoxin B1 (AFB1) induced hepatotoxicity
and gene expression changes underlying these eﬀects were investigated. Rats were orally administered three
doses (0.25 mg/kg, 0.5 mg/kg and 1.0 mg/kg) of AFB1 for seven days; after which blood was collected and liver
excised. Lipid proﬁles of plasma and liver were determined spectrophotometrically while the expression of genes
associated with lipid and lipoprotein metabolism was assayed by reverse transcriptase polymerase chain reac-
tion. Acute exposure to AFB1 increased the levels of plasma and liver cholesterol, triglycerides and phospho-
lipids. AFB1 at 0.5 mg/kg and 1.0 mg/kg resulted in a dose-dependent (1.2 and 1.5 fold, respectively) down-
regulation of hepatic Cpt1a with a concomitant 1.2 and 1.5 fold increase in the level of plasma FFA, respectively.
A similar observation of 1.2 and 1.3 fold increase was also observed in plasma triglyceride concentration, at both
respective doses. AFB1 also decreased the relative expression of Ahr, Lipc and Lcat whereas, it upregulated Scarb1
in a dose dependent manner. AFB1-induced dysregulation of the expression of lipid and lipoprotein metabolizing
genes may be one mechanism linking AFB1 to altered lipid metabolism and ultimately risk for coronary heart
disease.
1. Introduction
Aﬂatoxins are secondary metabolites synthesized by Aspergillus
fungi particularly Aspergillus ﬂavus and Aspergillus parasiticus [1,2].
They contaminate food and feedstuﬀ most especially grains and nuts
during pre - or post-harvest conditions in tropical regions speciﬁcally
sub-Saharan Africa and Southeast Asia [1,3]. Among the naturally oc-
curring aﬂatoxins that contaminate food signiﬁcantly (aﬂatoxin B1,
aﬂatoxin B2, aﬂatoxin G1, aﬂatoxin G2), aﬂatoxin B1 (AFB1) is the
most common and most toxic, and the liver is its key target organ [4–6].
In the liver, AFB1 is biotransformed by microsomal cytochrome P450 to
a highly reactive intermediate, AFB1-8, 9-epoxide which binds to nu-
cleic acids to form adducts [4,7,8]. These adducts could block tran-
scription and translation, thereby aﬀecting the regulation of functional
gene expression and ultimately causing hepatotoxicity [5]. AFB1-in-
duced hepatotoxicity also results from accumulation of reactive oxygen
species, which are precursors of hydroxyl radicals that interact with
DNA and lead to mutations [9,10]. AFB1 also induces apoptosis, cyto-
toxicity and genotoxicity in human hepatocytes (HepG2 cells) [11,12].
Acute aﬂatoxicosis resulting from exposure to high doses of AFB1
through the diet over a short period causes hepatotoxicity while chronic
aﬂatoxicosis resulting from exposure to low doses of AFB1 through the
diet over a long period of time has been implicated in hepatocellular
carcinoma [1,13]. Although acute aﬂatoxicosis is less common com-
pared with chronic aﬂatoxicosis it occurs occasionally and such out-
breaks have been reported in Kenya [14–16]. In an attempt to search
for potential biomarkers- using transcriptomics and metabolomics- for
earlier detection of AFB1 induced acute hepatotoxicity, Lu et al. [17]
reported that gluconeogenesis and lipid metabolism disorders are major
metabolic eﬀects following acute AFB1 exposure.
Lipids are molecules that play key roles in metabolic pathways and
the lipids of clinical and physiological signiﬁcance are fatty acids, tri-
glycerides, cholesterol and phospholipids [18]. These lipids are trans-
ported in the blood as lipoproteins which are made of a hydrophobic
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core surrounded by a hydrophilic layer [18,19]. Disturbances in the
homeostasis of these lipids and lipoproteins resulting in dyslipidemia
characterized by hypertriglyceridemia, low HDL-cholesterol and ele-
vated LDL- cholesterol are associated with various diseases including
cardiovascular disease [20–25]. Speciﬁcally abnormalities in lipopro-
tein levels and oxidation of LDL have been found to play a role in the
development of cardiovascular diseases in humans [26,27].
AFB1 has been reported to cause alterations in plasma and liver
lipid levels [2,4,17]. However, the doses at which these eﬀects occur
and the mechanisms underlying these alterations need further ex-
ploration. Lu et al. [17] reported that gene expression analysis and
metabolite proﬁling are more sensitive than general toxicity studies for
the detection of earlier hepatotoxicity induced by AFB1. The LD50 of
AFB1 has been reported to be 2.71 mg/kg and the authors reported that
no mortality was observed in rats treated with 1.0 mg/kg AFB1 [28].
Therefore, this study investigated the eﬀects of acute oral exposure to
three doses (0.25, 0.5 and 1.0 mg/kg) of AFB1, the doses were selected
to ensure there was no death during the experimental period, on lipid
and lipoprotein metabolism in rats and assessed expression of genes in
pathways relevant to lipid metabolism.
2. Materials and methods
2.1. Chemicals
AFB1 was a product of Sigma-Aldrich (St. Louis, MO). Reagent di-
agnostic kits were products of BioSino Biotechnology & Science Inc.
(Beijing, China). RNAlater® and RNA extraction spin column kit were
products of Aidlab Biotechnologies Co. Ltd (Beijing, China) while
TransGen EasyScript® one-step RT-PCR kit was a product of TransGen
Biotech Co. Ltd (Beijing, China). All other chemicals used in this study,
unless otherwise stated, were products of Sigma-Aldrich (St. Louis,
MO).
2.2. Animals
Twenty 10-week old inbred male albino rats weighing between 100
and 150 g were used for this research. The rats were housed in clean
cages, subjected to standard 12-h light and dark cycles and had access
to feed and clean tap water ad libitum. The animals were allowed to
acclimatize to their environment for one week before the experiment
started. The experiment was conducted, and animals cared for in ac-
cordance with the declaration of Helsinki.
2.3. Treatment protocol and tissue collection
The rats were randomly distributed into four treatment groups of
ﬁve rats each and treated with 0, 0.25, 0.5 or 1.0 mg/kg body weight
AFB1. AFB1 in olive oil was administered by oral gavage for seven days
while the control rats received equal volume of olive oil alone. The rats
were sacriﬁced on the eighth day, after an overnight fast, under an-
esthesia and blood collected by cardiac puncture. Blood and liver were
processed as previously described by Rotimi et al. [29] while a portion
of the left lobe was preserved in RNAlater® and another portion kept in
10% formalin for histological studies. Plasma was obtained from whole
blood by centrifugation at 3000 rpm for 15 min.
2.4. Biochemical analysis
2.4.1. Plasma lipid proﬁles
Total cholesterol and triglyceride concentrations in the plasma were
determined using commercially available kits according to the manu-
facturer’s instructions. Total HDL and HDL3 were recovered from the
plasma using dextran sulfate-MgCl2 precipitation at the ﬁnal con-
centration of 10 mg/mL dextran sulfate, 0.5 M MgCl2, 0.05% NaN3 and
19.1 mg/mL dextran sulfate, 1.95 M MgCl2, 0.05% NaN3, respectively
[30,31]. The supernatant, containing the lipoprotein, was recovered
after centrifugation at 1500 g for 30 min. Cholesterol and triglyceride
concentrations were determined in this supernatant with the same
commercial kits used for total cholesterol and triglyceride.
Plasma phospholipids were determined as described by Rifai et al.
[30], using 1-amino-2-naptho-4-sulphonic acid reagent, while free fatty
acids (FFA) were determined spectrophotometrically at 620 nm as de-
scribed by Rotimi et al. [32].
2.4.2. Liver lipid proﬁles
Lipids were extracted from the liver according to the method of
Folch et al. [33] and aliquots of the extract was used for determining
cholesterol, triglycerides and phospholipids as earlier described by
Rotimi et al. [34].
2.5. RNA extraction
RNA was extracted from RNAlater® – stabilized liver using the
Aidlab spin column RNA extraction kit according to the instructions of
the manufacturer. Concentration and purity of extracted RNA was de-
termined at 260 nm and 280 nm using a NanoDrop® 2000 spectro-
photometer (Thermo Scientiﬁc). RNA samples were kept at −80 °C
until gene expression analysis.
2.6. Expression of lipid metabolizing genes
The levels of expression of some lipid metabolizing genes were as-
sessed in the liver using semi-quantitative reverse transcriptase poly-
merase chain reaction (RT-PCR) as previously described by Rotimi et al.
[35]. Brieﬂy, the RT-PCR was carried out with 500 ng RNA template
using TranGen EasyScript one-step RT-PCR kit according to manu-
facturer’s instructions. The RNA samples were subjected to an initial
30 min incubation at 45 °C for cDNA synthesis after which PCR am-
pliﬁcation was carried out, using gene speciﬁc primers (GSP) (Table 1),
at 94 °C for 5 min followed by 40 cycles of 94 °C for 30 s, 5 min at the
annealing temperature of GSP, and 1 min at 72 °C. All ampliﬁcations
were carried out in C1000 Touch™ Thermal Cycler (Bio-Rad Labora-
tories, Hercules, CA). After PCR, amplicons were visualized on 1.2%
agarose gel in 1X Tris Borate EDTA buﬀer using UVP BioDoc-It™ Ima-
ging system (Upland, CA, USA). The intensity of the bands were ana-
lyzed using Image J software [36]. Results were presented as relative
expression (ratio of intensity of each gene to that of β-actin, Actb) of
each gene in comparison with a housekeeping (β-actin, Actb) gene.
There were no changes in the expression of the housekeeping gene
across the treatment groups.
2.7. Histopathology
A portion of liver samples were ﬁxed in 10% formalin immediately
after harvesting. The tissues were processed by cutting pieces in tissue
Table 1
Sequences of gene – speciﬁc primers.
Gene Sequence (5′–3′) Template
Ahr Forward: GGGCCAAGAGCTTCTTTGATG NM_001308255.1
Reverse: GCAAGTCCTGCCAGTCTCTGA
Lipc Forward: GAGCCCAGTCCCCCTTCA NM_012597.2
Reverse: ATGTCATTCTTTGCTGCGTCTC
Scarb1 Forward: GGCAAATTTGGCCTGTTCGT NM_031541.1
Reverse: CCACAGCAATGGCAGGACTA
Lcat Forward: AACTGGCTGTGCTACCGAAA NM_017024.2
Reverse: TAGGTCTTGCCAAAGCCAGG
Cpt1a Forward: AAGTCAACGGCAGAGCAGAG NM_031559.2
Reverse: ACGCCCAAGTATTCACAGGG
Actb Forward: GTCAGGTCATCACTATCGGCAAT NM_031144.3
Reverse: AGAGGTCTTTACGGATGTCAACGT
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cassettes with an automated tissue processor. They were then em-
bedded in paraﬃn and thereafter were sectioned with microtome. The
slides were then stained with haematoxylin and eosin.
2.8. Statistical analysis
Data were expressed as Mean ± SEM of ﬁve replicates. Analysis of
variance (ANOVA) was carried out to test for level of homogeneity at
p< 0.05 among the groups while Duncan multiple range test was used
to separate the heterogeneous groups. The ANOVA results was sub-
jected to contrast analysis to determine the linear dose-response (trend
analysis) among the groups using linear polynomial.
3. Results
3.1. Histology results
A comparison of the sections of the liver of control and AFB1 treated
animals showed that 0.25 mg/kg AFB1 resulted in minimal congestion
of hepatic lobules and microvesicular degeneration with few macro-
vesicles. Meanwhile the liver of rats treated with 0.50 mg/kg AFB1
indicated additional damages like inﬁltration by inﬂammatory cells
around the porta triad as well as congestion of the sinusoid and the
vessels. Further damage to the liver was observed at 1.0 mg/kg AFB1
treatment which included central vein (porto-central) inﬂammation,
numerous macrovesicles with inﬂammatory inﬁltrates on the portal
triad extending and reaching the contiguous portal triad (porto-porto),
and associated proliferation of the bile ductules (Fig. 1).
3.2. Lipid proﬁles
Acute exposure to AFB1 signiﬁcantly (p < 0.05) increased plasma
triglyceride (Fig. 2A) and FFA (Fig. 2B) in a dose dependent manner
with a signiﬁcant (p < 0.001) linear trend. While only the highest
dose (1.0 mg/kg) signiﬁcantly (p < 0.05) increased plasma total
cholesterol compared to the control group, there was a signiﬁcant
(p = 0.006) trend for a dose-dependent increase across groups. How-
ever, plasma phospholipid was signiﬁcantly decreased in the groups
exposed to 0.5 mg/kg and 1.0 mg/kg AFB1. Plasma phospholipid of the
group that received the lowest dose was not signiﬁcantly (p > 0.05)
diﬀerent from the control group. A signiﬁcant decrease in HDL3 cho-
lesterol was observed in groups exposed to 0.5 mg/kg and 1.0 mg, there
was a signiﬁcant (p = 0.004) trend for a dose-dependent decrease
across groups. However, there was no signiﬁcant diﬀerence in HDL
cholesterol (Fig. 3A), HDL-triglyceride (Fig. 3B) and HDL3-triglyceride
(Fig. 3D) among all the groups. The levels of hepatic cholesterol
(Fig. 4A), triglycerides (Fig. 4B) and phospholipids (Fig. 4C) were sig-
niﬁcantly (p < 0.05) increased by all the doses of AFB1. However,
only the increase in liver triglycerides was dose dependent, with a
signiﬁcant (p = 0.036) linear trend.
3.3. Relative expression of lipid metabolizing genes
The expression of ﬁve genes was assessed in liver samples from all
treatment groups. The relative expression of aryl hydrocarbon receptor
(Ahr) was signiﬁcantly (p < 0.05) decreased by only 0.5 mg/kg and
1.0 mg/kg AFB1 (Fig. 5A). All three doses used in this experiment
signiﬁcantly (p < 0.05) decreased, compared to control, the relative
expression of carnitine palmitoyl transferase 1A (Cpt1a) (Fig. 5B).
0.5 mg/kg AFB1 signiﬁcantly increased the relative expression of le-
cithin – cholesterol acyltransferase (Lcat) whereas 1.0 mg/kg AFB1
signiﬁcantly decreased the relative expression of Lcat compared with
the control (Fig. 5C). The relative expression of hepatic lipoprotein li-
pase (Lipc) was signiﬁcantly (p < 0.05) decreased in only the group
given 1.0 mg/kg AFB1 (Fig. 5D). However, 0.25, 0.5 and 1.0 mg/kg
AFB1 resulted in 15.8, 63.2, and 84.2% increases respectively in the
relative expression of scavenger receptor class B member 1 (Scarb1)
(Fig. 5E).
Fig. 1. Photomicrograph of liver tissues after aﬂa-
toxin B1 treatments with hematoxylin and eosin
staining. Representative slides are shown for each of
the four exposure groups: (A) control showing: (1)
portal triad and (2) central vein (B) 0.25 mg/kg
AFB1 showing: (1) microvesicles, (2) macrovesicles
and (3) portal triad (C) 0.50 mg/kg AFB1 showing:
(1) inﬂammatory cells, (2) portal triad, (3) central
vein and (4) microvesicles and (D) 1.0 mg/kg AFB1
showing (1) inﬂammatory cells, (2) hepatic artery,
(3) portal vein and (4) bile duct. Compared to the
control group, pathology of the 0.25 mg/kg was
minimal. In the 0.5 mg/kg group, sinusoid conges-
tion was evident along with inﬂammatory inﬁltra-
tion around the portal triad. In the highest dose
group, inﬂammation extended to the central vein
and the portal triad along with proﬁleration of the
bile ductules.
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4. Discussion
The results of this study conﬁrm several hallmarks of AFB1-induced
hepatotoxicity occur in a dose-dependent manner in a rat model testing
three sub-lethal doses and provide new insight into potential mechan-
isms underlying these eﬀects. The results demonstrate that AFB1 in-
duced hepatic damage with concomitant dyslipidemia, and this may
occur in part through the alteration of expression of lipid and lipo-
protein metabolising genes. The various degrees of histological damage
to the liver include inﬁltration of inﬂammatory cells around the portal
triad and bile duct proliferation which is consistent with other studies
[4,5,17]. Plasma dyslipidemia was characterized by increased con-
centrations of cholesterol, triglyceride and free fatty acids, and de-
creased concentrations of phospholipids and HDL3–cholesterol while
hepatic dyslipidemia was characterized by increased concentrations of
cholesterol, triglyceride and phospholipids. Expression of all ﬁve lipid-
related genes signiﬁcantly changed by AFB1 exposure. The doses of
AFB1 used in this study have been previously shown to induce acute
aﬂatoxicosis in rats without causing mortality [17,28].
Alterations in lipids and lipoproteins may play a role in the patho-
genesis of coronary heart diseases (CHD) [32,37,38]. Although, total
HDL-cholesterol has been known as “good” cholesterol which protects
from these diseases because of its ability to remove cholesterol from
peripheral tissues, other studies have indicated the importance of
studying the distinct subclasses of this lipoprotein because they remove
cholesterol from cells by diﬀerent mechanisms [39–41]. Kim and col-
leagues [42] discovered in their study, that HDL3-cholesterol may be
superior to total HDL-cholesterol and HDL2-cholesterol in predicting
the risk of coronary heart diseases. The ﬁndings of our study, which
showed that AFB1 decreased HDL3-cholesterol, coroborates this
Fig. 2. Eﬀects of Aﬂatoxin B1 on (A) plasma cho-
lesterol (B) plasma triglycerides (C) plasma free fatty
acids and (D) plasma phospholipid concentrations.
Bars represent the means ± SEM (n = 5). Bars with
diﬀerent alphabets are signiﬁcantly (p < 0.05) dif-
ferent from each other.
Fig. 3. Eﬀects of aﬂatoxin B1 on (A) HDL choles-
terol, (B) HDL triglycerides, (C) HDL3 cholesterol and
(D) HDL3 triglycerides concentrations.
Bars represent the means ± SEM (n = 5). Bars with
diﬀerent alphabets are signiﬁcantly (p < 0.05) dif-
ferent from each other.
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Fig. 4. Eﬀects of Aﬂatoxin B1 on (A) hepatic cho-
lesterol, (B) hepatic triglycerides and (C) hepatic
phospholipids.
Bars represent the means ± SEM (n = 5). Bars with
diﬀerent alphabets are signiﬁcantly (p < 0.05) dif-
ferent from each other.
Fig. 5. Eﬀects of Aﬂatoxin B1 on the relative ex-
pression of hepatic lipid metabolizing genes: (A) Ahr;
(B) Cpt1a; (C) Lcat; (D) Lipc; (E) Scarb1.
Bars represent the means ± SEM (n = 3). Relative
expression is ratio of intensity of each gene to that of
housekeeping gene (β-actin, Actb). Bars with dif-
ferent alphabets are signiﬁcantly (p < 0.05) dif-
ferent from each other.
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discovery.
A major ﬁnding of this study was that AFB1 increased free fatty
acids in a dose dependent manner. This is in agreement with Lu et al.
[17] who reported increased concentrations of long chain fatty acids;
9,12-octadecadienoic acid, trans-9-octadecanoic acid and octadecanoic
acid, after AFB1 administration. These ﬁndings could have resulted
from the down-regulation of Cpt1, an enzyme that facilitates the
transportation of long chain fatty acids into the mitochondria for β-
oxidation and subsequently formation of ATP [43,44]. Yarru et al. [44]
also observed down regulation of Cpt1 in chicks while Chen et al. [43]
reported that the reduction in Cpt1 observed in ducklings were not
statistically signiﬁcant. They however attributed this observation to the
low dose of AFB1 given to the ducklings, which indicates that down-
regulation of Cpt1 by AFB1 is dose dependent. On the other hand,
Zhang et al. [5] reported the upregulation of genes associated with
promoting fatty acid synthesis and elongation in ducklings. This study
conﬁrmed a AFB1 dose-dependent increase in FFA synthesis and su-
pression of Cpt1, which may be a mechanism underlying changes in
FFA. The excess FFA could be taken up by the liver and esteriﬁed to
form triglycerides or be mobilized for the synthesis of phospholipids.
The accumulation of phospholipid in tissue has been reported to be
induced by several xenobiotics [45]. This xenobiotic-induced phos-
pholipidosis has been reported to be due to enhanced FFA availability
and/or increased cholesterogenesis [46]. These two mechanisms might
be involved in the elevated level of liver phospholipid observed in this
study.
The AFB1-induced increase in both plasma and liver triglycerides
observed in this study is consistent with that of El-Nekeety et al. [2].
Over the years, hypertriglyceridemia have been reported to increase the
risk of CHD [47] and one enzyme involved in the regulation of plasma
triglyceride is hepatic lipase. Hepatic lipase is a lipolytic enzyme syn-
thesized by the hepatocytes [48], and found in the liver, adrenal glands
and ovaries [49]. Hepatic lipase, encoded by the gene Lipc, plays a
multifunctional role in lipoprotein metabolism, it regulates the pho-
pholipid, triglyceride and cholesterol content of lipoproteins because of
its role as a phospholipase and triglyceride lipase [47,49]. The role of
Lipc in atherosclerosis is unclear with some studies suggesting it is pro-
atherogenic and others anti-atherogenic [47–50]. This may be due to
complex responses of Lipc to various endogenous and exogenous fac-
tors. Our results showed that only the highest dose of AFB1 signiﬁcantly
decreased the expression of Lipc, suggesting other genes are involved in
lipoprotein metabolism changes observed in the lower AFB1 doses.
The present investigation shows that AFB1 increased the expression
of Scarb1 in a dose dependent manner. Scarb1 is a lipoprotein receptor,
belonging to the class B family of receptor, which regulates the selective
uptake of HDL-cholesterol esters (HDL-CE) [51–53]. Apart from this
major role, it appears to play a role in cholesterol metabolism, bi-di-
rectional cholesterol shuttling and could act as an anti-atherogenic
agent [53]. During reverse cholesterol transport, nascent HDL matures
into spherical HDL when HDL-free cholesterol is converted to HDL-CE
by Lcat [54]. The mature HDL delivers its CE, through a process
mediated by Scarb1, to the liver where it is hydrolyzed and excreated as
bilary cholesterol [54,55]. Although, the lowest dose of AFB1 upregu-
lated Lcat, the highest dose caused a down regulation. The increase in
the expression of Lcat observed could be as a result of increased need for
reverse cholesterol transport. However the highest AFB1 dose could
have overwhelmed this need. It is noteworthy that the group adminis-
tered the lowest dose (0.25 mg/kg) of AFB1 had the highest con-
centration of cholesterol in the liver as well as the highest expression of
Lcat, this could mean that AFB1 might have repressed the reverse
cholesterol transport. Scarb1 has been reported to perform the role of a
‘lipid trader’, therefore when the demand for HDL-cholesterol exceeds
its supply (due to downregulation of Lcat observed at the highest dose),
the trader actively seeks lipids [51]. Therefore, the upregulation of
Scarb1 observed in this study could be a response to change in lipid
homeostasis as well as protection against atherosclerosis [53].
The Aryl hydrocarbon receptor (Ahr) is a ligand- activated tran-
scription factor which plays a major role in xenobiotic metabolism [56]
and other biological processes including lipid metabolism [57–59].
Speciﬁcally, this receptor regulates fatty acid and cholesterol bio-
synthesis because its activation represses fatty acid synthesis and cho-
lesterol secretion in the liver [58,59]. In this study AFB1 repressed the
expression of Ahr which could account for the increase in lipids ob-
served in this study. Our results are consistent with that of Mary et al.
[60] who observed a decrease in the expression of Ahr mRNA levels in
spleen mononuclear cells of rats after 24 h of AFB1 treatment. Wada
et al. [57] reported upregulation of genes associated with lipogenesis in
high fat diet-induced hepatic steatosis using Ahr deﬁcient mice, they
concluded that Ahr may also play a role in protecting the liver against
lipotoxicity.
5. Conclusion
Acute exposure to high doses of AFB1 for seven days, induced liver
damage and dysregulation of lipid and lipoprotein metabolism through
altered expression of Cpt1a, Lipc, Lcat Scarb1 and Ahr genes which are
associated with lipid and lipoprotein metabolism. Notably, Cpt1 and
Scarb1 may be more sensitive indicators of aﬂatoxicosis as dose-de-
pendent expression changes occurred in these genes starting with the
lowest dose. Overall, the changes observed in this study may be asso-
ciated with increased risk of CHD and may play a critical role in acute
aﬂatoxicosis.
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